表紙
市場調査レポート

核画像診断 (PET・SPECT装置) の欧州市場 - 分析と予測

MediPoint: Nuclear Imaging - EU Analysis and Market Forecasts

発行 GlobalData 商品コード 321241
出版日 ページ情報 英文 270 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
核画像診断 (PET・SPECT装置) の欧州市場 - 分析と予測 MediPoint: Nuclear Imaging - EU Analysis and Market Forecasts
出版日: 2014年12月31日 ページ情報: 英文 270 Pages
概要

当レポートでは、欧州の核画像診断(PET・SPECT装置など)関連の市場について分析し、疾患の概要や市場構造、現在のアンメットニーズ、主な市場促進・抑制要因、今後の市場機会、現在治験中の主要製品、主要国における市場動向(過去3年間の実績値と今後7年間の予測値)、製品カテゴリー別の詳細動向、主要企業のプロファイルなどを調査しております

第1章 目次

第2章 イントロダクション

第3章 産業概要

  • 放射性画像技術
    • ポジトロン放射断層撮影 (PET)
    • 単光子放出コンピュータ断層撮影 (SPECT)
    • 平面シンチグラフィ
    • ハイブリッド型画像診断法
  • 核画像技術の臨床現場での用途
    • がん
    • 心臓病
    • 神経症
    • 感染症および炎症
  • 核画像診断技術の長所・短所
  • 市場へのアクセス
    • 製品のライフサイクル
    • 購入意思決定
    • 設備リース
    • PET/MRIによるPET/CTの交換
  • 償還
  • 処置の動向
  • 規制上の課題/リコール
  • M&Aおよび主な提携
  • 経済的影響

第4章 アンメットニーズ

  • 概要
  • 新技術に対する医療費償還の改善
  • 強制力のある臨床ガイドラインの欠如
  • 患者の快適性および便宜
  • 放射線曝露量の減少
  • スキャナの性能の改善
  • 画像処理ソフトウェアの改善
  • ハイブリッド型画像処理における人為的リスクの増加
  • 新しい放射性トレーサに対する需要
  • 設計プロセスへの臨床的入力の改善

第5章 市場機会の分析

  • より安くて簡単な核画像装置
  • 開発途上国でのSPECT/CT
  • テレラジオロジーサービスへの需要の増加

第6章 市場の促進要因および障壁

  • 促進要因:高齢者および有病者数の増加
  • 促進要因:医師の認知度の向上
  • 促進要因:防衛的医療
  • 促進要因:患者の認識
  • 促進要因:任意照会
  • 促進要因:新しい造影剤
  • 促進要因:がん診断検査の需要拡大
  • 促進要因:コンパニオン診断検査
  • 障壁:競合製品の有効性の研究
  • 障壁:医療費償還法案
  • 障壁:途上国市場での核画像診断の需要拡大
  • 障壁:不要な画像診断を減らすための保険会社のロビー活動
  • 障壁:EMRの保険調査の対象者の拡大
  • 障壁:不要な処置を減らす診療ガイドライン
  • 障壁:画像設備の認定
  • 障壁:核医学スキルの不足
  • 障壁:装置・試薬の高コスト性
  • 障壁:放射性医薬品のコスト・供給面での困難性
  • 障壁:医療機器への物品税
  • 障壁:病院の整理統合

第7章 競合評価

  • 概要
  • PET専用装置
    • 概要
    • 製品プロファイル
    • SWOT分析
  • PET/CT装置
  • PET/MRI装置
  • SPECT専用装置
  • SPECT/CT装置
  • PET/超音波およびSPECT/超音波装置

第8章 パイプライン製品の評価

  • 概要
  • 発展段階によるパイプライン製品
  • 製品プロファイル(全11製品)

第9章 注目の臨床検査

  • 概要
  • 治験のプロファイル

第10章 現在および将来の主要企業

  • 概要
  • 企業戦略の動向
  • 企業プロファイル
    • DDD-Diagnostic
    • Digirad
    • GE Healthcare
    • GVI Medical Devices
    • Mediso Medical Imaging Systems
    • NeuroLogica
    • Neusoft Medical Systems
    • NuCare Medical Systems
    • Oncovision
    • Philips Healthcare
    • 島津製作所
    • Siemens Healthcare
    • SurgicEye
    • 東芝メディカルシステムズ
    • その他の企業

第11章 市場の展望

  • 企業市場シェア分析
  • 市場セグメント別構成比
    • SPECTおよびSPECT/CT
    • PET、PET/CTおよびPET/MRI
  • 地域別
    • 概要
    • フランス
    • ドイツ
    • イタリア
    • スペイン
    • 英国

第12章 付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME1131CFR

This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine. The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand on struggling healthcare budgets. PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report PET imaging uses Positron Emitting radioactive tracers with a short half life, to image metabolically active organs PET combined with CT allows precise anatomical imaging of the body, identifying diseased areas depending upon the tracer used PET/CT is most often used for cancer diagnosis PET/MRI is a new technique that was introduced to reduce patient exposure to radiation PET only systems are now generally considered obsolete, due to the superior imaging quality of PET/CT

An early diagnosis of disease is the foundation of increasing survival rates. Single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging are diagnostic imaging techniques that are widely used in a variety of disease areas including oncology, cardiovascular disease, bone disease, and infectious disease. This report provides an analysis of the nuclear imaging market, with a particular focus on SPECT and PET imaging and hybrid modalities within the 5EU (France, Germany, Italy, Spain, and UK).

Scope

  • An overview of Nuclear Imaging, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
  • Annualized EU Nuclear Imaging market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
  • Investigation of current and future market competition for Nuclear Imaging.
  • Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
  • Competitor assessment including device approval analysis and device sales forecasts.
  • Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
  • Analysis of unmet needs within the market and opportunities for future players.
  • Technology trends evaluation to assess strength of pipeline.
  • An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
  • Company profiles including business description, financial overview and SWOT analysis.
  • Coverage of key market players.
  • Strategic assessment of the Nuclear Imaging sector through market impact analysis, future market scenario and company analysis.
  • Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

  • Understand the trends shaping and driving EU Nuclear Imaging market.
  • Realize device preferences of physicians who have performed the tests already.
  • Access market sizing, forecasts and quantified growth opportunities in EU Nuclear Imaging market through 2018.
  • Quantify candidate patient populations to better design product pricing & launch plans.
  • Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
  • Perform benchmarking analysis of growth opportunities against currently marketed products.
  • Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
  • Take a comprehensive look at the market's device pipeline and identify promising, paradigm-shifting products.
  • Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
  • What's the next big thing in EU Nuclear Imaging market landscape? Identify, understand and capitalize.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports

3. Industry Overview

  • 3.1. Nuclear Imaging Techniques
    • 3.1.1. Positron Emission Tomography
    • 3.1.2. Single-Photon Emission Computed Tomography
    • 3.1.3. Planar Scintigraphy
    • 3.1.4. Hybrid Imaging
  • 3.2. Clinical Applications of Nuclear Imaging Technology
    • 3.2.1. Cancer
    • 3.2.2. Cardiology
    • 3.2.3. Neurology
    • 3.2.4. Infection and Inflammation
  • 3.3. Advantages and Disadvantages of Nuclear Imaging Technologies
  • 3.4. Market Access
    • 3.4.1. Product Life Cycle
    • 3.4.2. Purchasing Decisions
    • 3.4.3. Equipment Leasing
    • 3.4.4. Replacement of PET/CT by PET/MRI
  • 3.5. Reimbursement
    • 3.5.1. Overview
    • 3.5.2. France
    • 3.5.3. Germany
    • 3.5.4. Italy
    • 3.5.5. Spain
    • 3.5.6. UK
  • 3.6. Procedure Trends
    • 3.6.1. France
    • 3.6.2. Germany
    • 3.6.3. Italy
    • 3.6.4. Spain
    • 3.6.5. UK
  • 3.7. Regulatory Issues/Recalls
  • 3.8. M&As and Key Partnerships
  • 3.9. Economic Impact

4. Unmet Needs

  • 4.1. Overview
  • 4.2. Improved Reimbursement for New Techniques
  • 4.3. Lack of Binding Clinical Guidelines
  • 4.4. Patient Comfort and Convenience
  • 4.5. Reducing Radiation Exposure
  • 4.6. Improved Scanner Performance
  • 4.7. Image Processing Software Improvements
  • 4.8. Increased Risk of Artifacts in Hybrid Images
  • 4.9. Demand for New Radiotracers
  • 4.10. Improved Clinical Input into the Design Process

5. Market Opportunity Analysis

  • 5.1. Cheaper, Simpler Nuclear Imaging Devices
  • 5.2. SPECT/CT in Developing Countries
  • 5.3. Increased Demand for Teleradiology Services

6. Market Drivers and Barriers

  • 6.1. Driver: Aging Population and Increasing Disease Prevalence
  • 6.2. Driver: Referring Physician Awareness
  • 6.3. Driver: Defensive medicine
  • 6.4. Driver: Patient Awareness
  • 6.5. Driver: Self-Referral
  • 6.6. Driver: New Imaging Agents
  • 6.7. Driver: Increasing Demand for Cancer Diagnostic Tests
  • 6.8. Driver: Companion Diagnostic Testing
  • 6.9. Barrier: Comparative Effectiveness Research
  • 6.10. Barrier: Reimbursement Legislation
  • 6.11. Barrier: Increasing Demand for Nuclear Imaging in Developing Markets
  • 6.12. Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging
  • 6.13. Barrier: Greater Payer Scrutiny of EMRs
  • 6.14. Barrier: Increased Use of Appropriateness Criteria
  • 6.15. Barrier: Practice Guidelines to Reduce Unnecessary Procedures
  • 6.16. Barrier: Imaging Facility Accreditation
  • 6.17. Barrier: Loss of Nuclear Medicine Skills
  • 6.18. Barrier: High Cost of Instruments and Reagents
  • 6.19. Barrier: Radiopharmaceutical Cost and Supply Difficulties
  • 6.20. Barrier: Hospital Consolidation

7. Competitive Assessment

  • 7.1. Overview
  • 7.2. Dedicated PET Systems
    • 7.2.1. Overview
    • 7.2.2. Product Profile
    • 7.2.3. SWOT Analysis
  • 7.3. PET/CT Systems
    • 7.3.1. Overview
    • 7.3.2. Product Profiles
    • 7.3.3. SWOT Analysis
  • 7.4. PET/MRI Systems
    • 7.4.1. Overview
    • 7.4.2. Product Profile
    • 7.4.3. SWOT Analysis
  • 7.5. Dedicated SPECT Systems
    • 7.5.1. Overview
    • 7.5.2. Product Profile
    • 7.5.3. SWOT Analysis
  • 7.6. SPECT/CT Systems
    • 7.6.1. Overview
    • 7.6.2. Product Profile
    • 7.6.3. SWOT Analysis
  • 7.7. PET/Ultrasound and SPECT/Ultrasound Systems
    • 7.7.1. Overview
    • 7.7.2. Product Profile
    • 7.7.3. SWOT Analysis

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Pipeline by Phases in Development
  • 8.3. Product Profiles
    • 8.3.1. Brain Biosciences CerePET
    • 8.3.2. ECORAD Dual Modality Imager
    • 8.3.3. FMI Technologies ScintiStar PET/CT
    • 8.3.4. IntraMedical Imaging Marginator Beta Camera
    • 8.3.5. INSERT SPECT/MRI
    • 8.3.6. Nucare/Zecotek Photonics New Generation PET Scanning Device
    • 8.3.7. Philips Healthcare PET Alpha Ring Detector
    • 8.3.8. Photo Diagnostic Systems NeuroPET/CT
    • 8.3.9. SynchroPET Breast PET/MRI
    • 8.3.10. SynchroPET Wrist Scanner
    • 8.3.11. SurgicEye SPECT Hybrid

9. Clinical Trials to Watch

  • 9.1. Overview
  • 9.2. Clinical Trial Profiles

10. Current and Future Players

  • 10.1. Overview
  • 10.2. Trends in Corporate Strategy
  • 10.3. Company Profiles
    • 10.3.1. DDD-Diagnostic
    • 10.3.2. Digirad
    • 10.3.3. GE Healthcare
    • 10.3.4. GVI Medical Devices
    • 10.3.5. Mediso Medical Imaging Systems
    • 10.3.6. NeuroLogica
    • 10.3.7. Neusoft Medical Systems
    • 10.3.8. NuCare Medical Systems
    • 10.3.9. Oncovision
    • 10.3.10. Philips Healthcare
    • 10.3.11. Shimadzu
    • 10.3.12. Siemens Healthcare
    • 10.3.13. SurgicEye
    • 10.3.14. Toshiba Medical
    • 10.3.15. Other Companies

11. Market Outlooks

  • 11.1. Company Market Share Analysis
    • 11.1.1. Overview
    • 11.1.2. France
    • 11.1.3. Germany
    • 11.1.4. Italy
    • 11.1.5. Spain
    • 11.1.6. UK
  • 11.2. Market Segment Share
    • 11.2.1. SPECT & SPECT/CT
    • 11.2.2. PET, PET/CT & PET/MRI
  • 11.3. By Geography
    • 11.3.1. Overview
    • 11.3.2. France
    • 11.3.3. Germany
    • 11.3.4. Italy
    • 11.3.5. Spain
    • 11.3.6. UK

12. Appendix

  • 12.1. Abbreviations
  • 12.2. Bibliography
  • 12.3. Methodology
    • 12.3.1. Overview
    • 12.3.2. Coverage
    • 12.3.3. Secondary Research
  • 12.4. Physicians and Specialists Included in This Study
  • 12.5. Primary Research
    • 12.5.1. Primary Research - Key Opinion Leader Interviews
    • 12.5.2. Expert Panel Validation
    • 12.5.3. Stakeholder Survey
  • 12.6. Forecasting Methodology
  • 12.7. About the Authors
    • 12.7.1. Andrew Thompson, PhD, Senior Analyst
    • 12.7.2. Priya Radhakrishnan, MBA, Director, Medical Devices
    • 12.7.3. Bonnie Bain, PhD, Global Head of Healthcare
  • 12.8. About GlobalData
  • 12.9. Disclaimer

List of Tables

  • Table 1: Applications of Nuclear Imaging
  • Table 2: FDG-PET Diagnostic Accuracy for Specific Cancers
  • Table 3: Potential Clinical Benefits of Hybrid Nuclear Imaging in Cardiology
  • Table 4: Applications of PET Imaging in Non-Cancer Neurology
  • Table 5: Applications of SPECT Imaging in Non-Cancer Neurology
  • Table 6: Characteristics of SPECT, PET, Ultrasound, CT, and MRI
  • Table 7: The Age of Canada's Hospital-Based Medical Technology Inventories, Relative to ECCREI Rules, 2009
  • Table 8: Nuclear Imaging Trends in France, 2012-2020
  • Table 9: Nuclear Imaging Trends in Germany, 2012-2020
  • Table 10: Nuclear Imaging Trends in Italy, 2012-2020
  • Table 11: Nuclear Imaging Trends in Spain, 2012-2020
  • Table 12: Nuclear Imaging Trends in UK, 2012-2020
  • Table 13: Recent Device Recalls in the Nuclear Imaging Market
  • Table 14: Recent Key Events in the Nuclear Imaging Market
  • Table 15: Nuclear Imaging Market Drivers and Barriers
  • Table 16: Duplicate Diagnostic Test Incidence in France, Germany, UK, and US
  • Table 17: Dedicated PET Scanners
  • Table 18: Dedicated PET SWOT Analysis
  • Table 19: PET/CT Scanners
  • Table 20: PET/CT SWOT Analysis
  • Table 21: PET/MRI Systems
  • Table 22: PET/MRI SWOT Analysis
  • Table 23: Dedicated SPECT Systems
  • Table 24: Dedicated SPECT SWOT Analysis
  • Table 25: SPECT/CT Systems
  • Table 26: SPECT/CT SWOT Analysis
  • Table 27: SPECT-Ultrasound Systems
  • Table 28: SPECT/Ultrasound SWOT Analysis
  • Table 29: Nuclear Imaging Pipeline, 2014
  • Table 30: CerePET SWOT Analysis
  • Table 31: ECORAD Dual Modality Imager SWOT Analysis
  • Table 32: ScintiStar PET/CT SWOT Analysis
  • Table 33: Marginator SWOT Analysis
  • Table 34: INSERT SPECT-MRI SWOT Analysis
  • Table 35: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis
  • Table 36: PET Alpha Ring Detector
  • Table 37: NeuroPET/CT Scanner SWOT Analysis
  • Table 38: SynchroPET Breast PET/MRI SWOT Analysis
  • Table 39: SynchroPET Wrist Scanner
  • Table 40: SurgicEye SPECT/Ultrasound device SWOT Analysis
  • Table 41: Key Clinical Trials
  • Table 42: Company Profile - DDD-Diagnostic
  • Table 43: DDD-Diagnostic SWOT Analysis
  • Table 44: Company Profile - Digirad
  • Table 45: Digirad SWOT Analysis
  • Table 46: Company Profile - GE Healthcare
  • Table 47: GE Healthcare Product Portfolio
  • Table 48: GE Healthcare SWOT Analysis
  • Table 49: Company Profile - GVI Medical Devices
  • Table 50: GVI Medical Devices SWOT Analysis
  • Table 51: Company Profile - Mediso Medical Imaging Systems
  • Table 52: Mediso Medical Imaging Systems SWOT Analysis
  • Table 53: Company Profile - Neurologica
  • Table 54: Neurologica SWOT Analysis
  • Table 55: Company Profile - Neusoft Medical Systems
  • Table 56: Neusoft Medical Systems SWOT Analysis
  • Table 57: Company Profile - NuCare Medical Systems
  • Table 58: Nucare Medical Systems SWOT Analysis
  • Table 59: Company Profile - Oncovision
  • Table 60: Oncovision SWOT Analysis
  • Table 61: Company Profile - Philips Healthcare
  • Table 62: Philips Healthcare SWOT Analysis
  • Table 63: Company Profile - Shimadzu
  • Table 64: Shimadzu SWOT Analysis
  • Table 65: Company Profile - Siemens Healthcare
  • Table 66: Siemens Healthcare SWOT Analysis
  • Table 67: Company Profile - SurgicEye
  • Table 68: SurgicEye SWOT Analysis
  • Table 69: Company Profile - Toshiba Medical
  • Table 70: Toshiba Medical SWOT Analysis
  • Table 71: Other Companies in the Nuclear Imaging Market, 2014
  • Table 72: EU5 Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020)
  • Table 73: EU5 Market Value Forecast by Market Segment for PET, PET/CT & PET/MRI (2012-2020)
  • Table 74: EU5 Sales of PET and SPECT Imaging Systems, 2012-2020
  • Table 75: France Market Value Forecast by Market Sub segment (2012-2020)
  • Table 76: Germany Market Value Forecast by Market Sub segment (2012-2020)
  • Table 77: Italy Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 78: Spain Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 79: UK Market Value Forecast by Market Sub-segment (2012-2020)
  • Table 80: Primary Research Summary
  • Table 81: Primary Research Participants Affiliation

List of Figures

  • Figure 1: Cyclotron Distribution in 10 Countries
  • Figure 2: Localization of Tumor in Chest Cavity by PET, CT, and PET/CT
  • Figure 3: Mutually Beneficial Effects of PET/MRI Imaging
  • Figure 4: Nuclear Imaging Trends in France, 2012-2020
  • Figure 5: Nuclear Imaging Trends in Germany, 2012-2020
  • Figure 6: Nuclear Imaging Trends in Italy, 2012-2020
  • Figure 7: Nuclear Imaging Trends in Spain, 2012-2020
  • Figure 8: Nuclear Imaging Trends in UK, 2012-2020
  • Figure 9: Imaging Utilization Rates (Number of Outpatient Visits with MRI/CT per 1,000 Persons), by Year in the US
  • Figure 10: EU5 Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 11: France Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 12: Germany Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 13: Italy Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 14: Spain Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 15: UK Company Market Shares for Nuclear Imaging Equipment (2012)
  • Figure 16: EU5 Market Value Forecast by Market Segment for SPECT & SPECT/CT (2012-2020)
  • Figure 17: EU5 Market Value Forecast by Market Segment for PET, PET/CT, and PET/MRI (2012-2020)
  • Figure 18: EU5 Sales of PET and SPECT Imaging Systems, 2012-2020
  • Figure 19: France Market Value Forecast by Market Subsegment (2012-2020)
  • Figure 20: Germany Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 21: Italy Market Value Forecast by Market Sub segment (2012-2020)
  • Figure 22: Spain Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 23: UK Market Value Forecast by Market Sub-segment (2012-2020)
  • Figure 24: Primary Research Summary
  • Figure 25: Primary Research Participants Affiliation
Back to Top